ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,897,000 | +53.8% | 50,700 | +2.0% | 0.14% | +52.8% |
| Q1 2018 | $2,534,000 | -30.0% | 49,700 | -36.4% | 0.09% | -19.8% |
| Q4 2017 | $3,622,000 | -12.9% | 78,100 | 0.0% | 0.11% | -36.9% |
| Q3 2017 | $4,160,000 | -14.2% | 78,100 | 0.0% | 0.18% | +144.4% |
| Q2 2017 | $4,851,000 | -8.4% | 78,100 | 0.0% | 0.07% | -14.3% |
| Q1 2017 | $5,294,000 | +13.4% | 78,100 | +17.6% | 0.08% | +2.4% |
| Q4 2016 | $4,669,000 | -11.4% | 66,400 | -10.6% | 0.08% | -11.8% |
| Q3 2016 | $5,271,000 | +42.2% | 74,300 | -2.0% | 0.09% | +63.2% |
| Q2 2016 | $3,707,000 | +54.5% | 75,800 | +100.0% | 0.06% | +42.5% |
| Q1 2016 | $2,399,000 | -34.2% | 37,900 | +16.6% | 0.04% | -29.8% |
| Q4 2015 | $3,646,000 | +78.6% | 32,500 | +53.3% | 0.06% | +62.9% |
| Q3 2015 | $2,042,000 | – | 21,200 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |